A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
Study sponsor: Annovis Bio Inc. · ANVS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-02-13Actual
Enrollment · participants351Actual
Source updated2025-04-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.